Apical Hypertrophic Cardiomyopathy: A Clinical & Multimodality Imaging Assessment
Echocardiography · 2025-07 · 42 (7)
DOI: 10.1111/echo.70235 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Echocardiography, online erschienen am 18.07.2025. Verfasst von Izhan Hamza und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Multimodal Imaging, Echocardiography, Heart Ventricles. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 77 Literaturangaben.
Abstract (Originalsprache)
Apical Hypertrophic Cardiomyopathy (ApHCM) is a distinct phenotypic variant of hypertrophic cardiomyopathy, defined by localized thickening of the left ventricular (LV) apex ≥15 mm in end‐diastole. It presents unique diagnostic and management challenges, with clinical presentations ranging from asymptomatic individuals to those experiencing angina, dyspnea, or arrhythmias. Transthoracic echocardiography remains the first‐line imaging modality but is often limited by suboptimal apical visualization. Contrast‐enhanced echocardiography is recommended to improve diagnostic accuracy, particularly for identifying apical hypertrophy, apical aneurysms, and thrombi. Echocardiography also plays a key role in assessing left ventricular outflow tract obstruction, detecting concomitant mitral valve abnormalities, and guiding periprocedural planning. Cardiac magnetic resonance imaging (CMR) provides superior spatial resolution and tissue characterization. It is the gold standard for evaluating apical wall thickness, detecting apical aneurysms, and quantifying myocardial fibrosis through late gadolinium enhancement. CMR‐based markers such as LGE burden and aneurysm size are valuable for sudden cardiac death risk stratification. Additional imaging modalities, including cardiac computed tomography and nuclear perfusion imaging, are important adjuncts when CMR is contraindicated or when evaluation for coronary artery disease is necessary. This review underscores the central role of multimodality imaging in the diagnosis, risk assessment, and management of ApHCM. Future research should focus on refining risk prediction tools to improve individualized care and clinical outcomes in this unique cardiomyopathy subtype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA.
- Division of Cardiovascular Medicine, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA.
ORCID-Profile: Masood Ahmad
Zitieren
APA
Hamza, I., Odigie-Okon, E., Xie, T., & Ahmad, M. (2025). Apical Hypertrophic Cardiomyopathy: A Clinical & Multimodality Imaging Assessment. Echocardiography, 42(7). https://doi.org/10.1111/echo.70235
Vancouver
Hamza I, Odigie-Okon E, Xie T, Ahmad M. Apical Hypertrophic Cardiomyopathy: A Clinical & Multimodality Imaging Assessment. Echocardiography. 2025;42(7). doi:10.1111/echo.70235
BibTeX
@article{Hamza2025,
author = {Hamza, Izhan and Odigie-Okon, Esosa and Xie, Tianrong and Ahmad, Masood},
title = {Apical Hypertrophic Cardiomyopathy: A Clinical & Multimodality Imaging Assessment},
journal = {Echocardiography},
year = {2025},
volume = {42},
number = {7},
doi = {10.1111/echo.70235}
}
EUVIMED